Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

S5 Fig - by Meihui Chen (1670020)

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

Endoscopic injection into the vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Distribution of miRs with a greater than two fold-change. by Stephanie L. Samani (17896610)

Subjects:

Fig 5 - by Andrea R. Thurman (5286005)

LOH resulting in 189R/R produces a strong decrease in drug susceptibility. by Pétra Vande Zande (17628246)

Injection and evaluation of GFP-labelled DFATs in vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Subnetwork of core DE genes with ≥5.0 degree and a fold change of ≥2.0 (50 nodes and 97 edges). by Reena Arora (1464781)

Effect of DFATs implantation on the inhibition of atrophy in the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

A heat map was generated for all the miRs utilized in the array, as a function of a fold change from referent control values. by Stephanie L. Samani (17896610)

Subjects:

Effect of DFATs transplantation on collagen accumulation within the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Analysis of apoptotic cells within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

Assessment of the viability of DFATs within the vocal fold muscle using GFP immunostaining. by Ikuo Mikoshiba (9312007)

Subjects:

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”